ALPHAMAB ONCOLO.DL-000002 (3NK) — Net Asset Quality Index
ALPHAMAB ONCOLO.DL-000002 (3NK) has a Net Asset Quality Index of 81.6% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €2.10 Billion minus total liabilities of €386.17 Million yields net assets of €1.71 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 3NK cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
ALPHAMAB ONCOLO.DL-000002 Net Asset Quality Index Over Time (2021–2025)
This chart shows how ALPHAMAB ONCOLO.DL-000002's Net Asset Quality Index has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the index stands at 81.6%, representing net assets of €1.71 Billion against total assets of €2.10 Billion EUR. See working capital position of ALPHAMAB ONCOLO.DL-000002 to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for ALPHAMAB ONCOLO.DL-000002 (2021–2025)
The table below presents the year-by-year Net Asset Quality Index for ALPHAMAB ONCOLO.DL-000002 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see ALPHAMAB ONCOLO.DL-000002 (3NK) market capitalisation.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 81.6% | €1.71 Billion | €2.10 Billion | €386.17 Million | ▼ -0.1 pp |
| 2024 | 81.7% | €1.83 Billion | €2.24 Billion | €409.87 Million | ▲ +3.5 pp |
| 2023 | 78.2% | €1.67 Billion | €2.14 Billion | €465.00 Million | ▲ +4.7 pp |
| 2022 | 73.6% | €1.56 Billion | €2.12 Billion | €559.86 Million | ▲ +4.4 pp |
| 2021 | 69.1% | €1.87 Billion | €2.71 Billion | €834.80 Million | — |